Literature DB >> 29249564

Synchronous tumours of the female reproductive tract.

C Blake Gilks1, Friedrich Kommoss2.   

Abstract

Many ovarian endometrioid carcinomas present with concurrent endometrial carcinoma, and these organ-confined, low-grade synchronous endometrial and ovarian tumours consistently behave as independent primary tumours, rather than a single advanced-stage carcinoma; they are associated with a very favourable prognosis and there is no need for adjuvant treatment. This phenomenon of synchronous tumours involving two or more sites within the female reproductive tract is well recognised, occurring in 1-2% of cases. Although some tumours can be recognised as metastasis, in many the relationship between the synchronous tumours is uncertain. Recently, application of next generation sequencing to synchronous endometrial and ovarian carcinomas has shed light on the relationship between these tumours, but raised more questions about the biology of this curious phenomenon. Herein, we review synchronous tumours involving more than one site in the female genital tract, discuss the pathogenesis, and offer guidelines for how to handle in routine practice.
Copyright © 2017 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Synchronous; independent primaries; metastasis; pseudometastasis

Mesh:

Year:  2017        PMID: 29249564     DOI: 10.1016/j.pathol.2017.10.007

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  2 in total

1.  Preoperative predictive factor analysis of ovarian malignant involvement in premenopausal patients with clinical stage I endometrioid endometrial carcinoma.

Authors:  Qin Chen; Yan Feng; Wenwen Wang; Weiguo Lv; Baohua Li
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 2.  A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer.

Authors:  Shuangfeng Chen; Yuebo Li; Lili Qian; Sisi Deng; Luwen Liu; Weihua Xiao; Ying Zhou
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.